Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Co

Published economic health study shows both short- and long-term cost-effectiveness of replacement ve

Published economic health study shows both short- and long-term cost-effectiveness of replacement ve

enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(5.37) per share. This is a 53.51 percen

Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivot

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe

EnVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today

New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous V

- Live webcast on Wednesday, June 24th at 2:00 PM ET - Access the event here IRVINE, CA / ACCESS New

Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June

First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE

enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(5.89) per share which missed the analys

Company ended the first quarter with approximately $25 million in cash and investments Capital on ha

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and

enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(6.05) per share which missed the analys

Company accelerated development of the enVVe® System, completing pre-clinical studies and progressin

NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund

Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free R

LENSAR (NASDAQ: LNSR - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free Report) are bot

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter

enVVeno Medical Corporation (NASDAQ: NVNO)'s stock is going to reverse split on the morning of Tuesd

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), toda

IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVen

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, Decem

IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVe

- Cash and investments are sufficient to fund current operations through Q2 2027, not including Veno